# Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy

> **NCT02210819** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1987 (actual)

## Conditions studied

- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Recommended VTE pharmacological treatments according to international guidelines

## Key facts

- **NCT ID:** NCT02210819
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-27
- **Primary completion:** 2016-11-03
- **Final completion:** 2017-01-20
- **Target enrollment:** 1987 (ACTUAL)
- **Last updated:** 2019-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02210819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02210819, "Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02210819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*